KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Receivables - Accured (2022 - 2025)

Arbutus Biopharma (ABUS) has disclosed Revenue - Other for 5 consecutive years, with $721000.0 as the latest value for Q2 2017.

  • Quarterly Revenue - Other rose 160.29% to $721000.0 in Q2 2017 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Jun 2017, down 81.87% year-over-year, with the annual reading at $10.0 million for FY2017, 693.82% up from the prior year.
  • Receivables - Accured hit $300000.0 in Q4 2025 for Arbutus Biopharma, roughly flat from $300000.0 in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $600000.0 in Q4 2022 to a low of $100000.0 in Q2 2025.
  • Historically, Receivables - Accured has averaged $415384.6 across 4 years, with a median of $300000.0 in 2024.
  • Biggest five-year swings in Revenue - Other: soared 39100.0% in 2014 and later plummeted 97.62% in 2016.
  • Year by year, Revenue - Other stood at $5.0 million in 2013, then crashed by 79.54% to $1.0 million in 2014, then surged by 705.67% to $8.2 million in 2015, then tumbled by 97.62% to $196000.0 in 2016, then surged by 267.86% to $721000.0 in 2017.
  • Business Quant data shows Revenue - Other for ABUS at $721000.0 in Q2 2017, $217000.0 in Q1 2017, and $196000.0 in Q4 2016.